Celgene Corp
Price
$108.42
Today
+0.0%
YTD
+0.0%
Celgene Corporation dates back to 1986 and is a global biopharmaceutical company primarily engaged in the development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases in patients with limited treatment options. The company’s portfolio of commercial products includes REVLIMID®, VIDAZA®, THALOMID®, POMALYST®/IMNOVID®, ABRAXANE®, OTEZLA®, ISTODAX® and IDHIFA®. Celgene’s operating and financial results for the second quarter of fiscal 2018 included a 17% increase in total net product sales to $3.8 billion. Follow and trade CELG for more news and updates.
No daily candle data is currently available for this instrument.
Open positions
0
Unrealized return
+0.0%
No open positions exist for this instrument at the moment.
Valuation
Profitability
Earnings & Revenue
Dividends & Risk
Closed trades
0
Realized return
+0.0%
No stored closed trades exist for this instrument yet.